Bovenden, Germany

Hansjörg Eibl

This inventor holds 3 USPTO granted patents. Top assignee: Other. Active years: 2001-2003.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 39(Granted Patents)


Location History:

  • Bovenden-Eddigehausen, DE (2001 - 2003)
  • Bovenden, DE (2003)

Company Filing History:

goldMedal3 out of 834,411 
Other
 patents

Years Active: 2001-2003

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Hansjörg Eibl

Introduction

Hansjörg Eibl is a notable inventor based in Bovenden, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of cationic lipids and methods for treating protozoal diseases. With a total of 3 patents, Eibl's work has the potential to impact various medical applications.

Latest Patents

One of Hansjörg Eibl's latest patents involves cationic lipids. These lipids are particularly useful in the preparation of liposomes and other lipid vesicle carriers. They serve as effective carriers for nucleic acids and other negatively charged substances, facilitating their delivery to cells. Another significant patent focuses on methods of treating protozoal diseases, showcasing Eibl's commitment to addressing critical health challenges.

Career Highlights

Throughout his career, Hansjörg Eibl has demonstrated a strong dedication to innovation in biotechnology. His work has not only advanced scientific understanding but also provided practical solutions for medical applications.

Collaborations

Eibl has collaborated with notable colleagues such as Clemens Unger and Jürgen Engel, further enhancing the impact of his research and inventions.

Conclusion

Hansjörg Eibl's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and technologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…